RiboNovix, Inc. Developing Anti-Infectives That Are Less Susceptible To Antibiotic Resistance
10/19/2005 5:11:45 PM
New biotechnology company, RiboNovix, Inc., is addressing the worsening problem of antibiotic-resistant bacteria by developing new anti-infectives that are less susceptible to drug resistance. Over the last few months, RiboNovix has completed an exclusive license agreement with Wayne State University for the rights to a novel functional genomics platform technology developed in the laboratories of Dr. Philip Cunningham, assembled a team of leading researchers in the field of antibiotic resistance, and been awarded a $346,066 Phase I SBIR grant by the National Institutes of Health.
comments powered by